dual gip and glp-1 receptor agonist GLP1-GIP co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Frontiers | Clinical perspectives on
Description
Currently, GLP-1s are probably most well-known for their weight loss effects, with studies showing people with overweight and obesity lose an average of 10 pounds or more using them
This agent differs from earlier therapies that were designed to reduce myocardial loading or induce neurohumoral blockade
has done educational work for Eli Lilly and Novo Nordisk
Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
Digital platforms now offer structured consultations, remote monitoring, and medication management for obesity treatment
